Phase 1 N=27 Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza Type A · Influenza Type B · Influenza
Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=257 A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva
Healthy Volunteers
Primary: AUC0-last — 146000; 134000; 138000 day*ng/mL
Phase 1 N=32 Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics
Asthma
Primary: Number of Treatment-emergent Adverse Events and Serious Adverse Events — 19; 17; 12; 9 adverse events
Phase 1 N=95 Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test and IS — 0.19; -0.12; -0.76; -0.24 Scores on a scale
Phase 1 N=40 Sleep and Healthy Aging Research on Depression for Younger Women
Anhedonia · Depression
Primary: Non-social (Monetary) Reward Response (Reward Learning and Sensitivity) — .563; .307; .309; .366 response bias — p=.16
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 1 N=192 Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Nemolizumab — 8.00; 7.51 micrograms per milliliter (mcg/mL)
Phase 1 N=16 Phase 1b Study of DCR-AUD in Healthy Volunteers
Alcohol Use Disorder
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 11; 3; 0; 0 Participants
Phase 1 N=19 A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
Drug Interaction
Primary: To Evaluate the Impact of C21 on the Pharmacokinetics (PK) of Caffeine and Paraxanthine (Cmax) — 2290; 2871; 2784; 546.4 ng/mL
Phase 1 N=23 A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Phase 1 N=35 Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
Safety Issues · Pharmacokinetics · Drug Interaction
Primary: Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-inf — 13950; 42840; 137.3; 165.9 h*nmol/L
Phase 1 N=11 Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Hepatitis C, Chronic
Primary: Maximum Concentration of Velpatasvir in Maternal Plasma — 381.93 ng/mL
Phase 1 N=3 A BCT Intervention for Physical Activity Among Individuals on Statins
Insufficient Physical Activity
Primary: Number of Participants Who Achieved a 2,000 Step/Day Increase Between run-in and Follow-up — 7 Participants
Phase 1 N=12 A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males
No Condition
Primary: Plasma PK Concentrations and Parameters of Ketoprofen (Part A): Area Under the Concentration-time Curve (AUC) From Zero to the Last Quantifiable Concentrations (AUC0-t)…
Phase 1 N=264 Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Neoplasms
Primary: Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) — 1; 1; 2; 7 Participants